🇺🇸 FDA
Patent

US 6210913

Modulation of integrin-mediated signal transduction

expired A61PA61P29/00A61P35/00

Quick answer

US patent 6210913 (Modulation of integrin-mediated signal transduction) held by COR Therapeutics, Inc. expires Mon Mar 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
COR Therapeutics, Inc.
Grant date
Tue Apr 03 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P29/00, A61P35/00, A61P43/00, A61P7/02